Diabetes mellitus and ischemic heart disease

Czech version

Authors: I. Dresslerová; J. Vojáček
Authors‘ workplace: I. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MU Dr. Jan Vojáček, DrSc., FESC, FACC
Published in: Vnitř Lék 2010; 56(4): 301-306
Category: 11th National Diabetes Symposium "Diabetes and Angiology", Hradec Kralove, 5 to 6 June 2009

Overview

Diabetes mellitus (DM) is closely associated with cardiovascular (CV) diseases. These are the main cause of death in patients not only with type 2 but also type 1 diabetes. Apart from the traditional risk factors such as arterial hypertension, dyslipidemia and obesity, hyperglycaemia is an independent risk factor for the development of ischemic heart disease (IHD). Long‑term hyperglycaemia leads to vascular damage through several mechanisms. These include oxidative stress, formation of advanced glycation end products, activation of the nuclear factor κ B and decreased production of nitrogen monoxide (NO). Insulin resistance is believed to have an important bearing on pathogenesis of IHD in type 2 diabetes (DM2) patients. The course of IHD in diabetic patients is usually more complicated. Direct percutaneous coronary intervention (PCI) is the gold standard in the treatment of myocardial infarction (MI) in diabetic as well as non‑diabetic patients. Drug‑eluting stents, associated with fewer reocclusions, have also proved useful. In addition to drug‑eluting stent implantation, surgical revascularization, preferably utilizing internal thoracic artery, is a suitable technique in patients without acute coronary syndrome indicated for an intervention. Conservative approach should be applied in less severely affected patients. IHD prevention should include appropriate control of arterial hypertension, dyslipidemia and weigh reduction. Diabetes treatment should be managed individually and with respect to the potential risk of hypoglycaemia in high‑risk patients with longer duration of diabetes and known CV disease. Newly diagnosed type 2 diabetes patients should from the onset be treated with metformin and tight compensation should be aimed for with target value for glycated haemoglobin of less than 4.5% (IFCC methodology). Evidence exists that this approach may significantly reduce the CV risk. Intensified insulin regimen is the most suitable treatment approach for the type 1 diabetes patients also with respect to microvascular and macrovascular complication prevention. Treatment of hyperglycaemia is one of the set of measures that may contribute to CV risk reduction in diabetic patients.

Key words:
diabetes mellitus – ischemic heart disease – cardiovascular risk – myocardial infarction – IHD prevention – glycaemia

Sources

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002; 287: 2570– 2581.

2. Milicevic Z, Raz I, Beattie SD. Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care 2008; 31 (Suppl 2): S155– S160.

3. Kannel WB. Lipids, diabetes and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100– 1107.

4. Haffner SM. Coronary heart disease in patients with diabetes. N Eng J Med 2000; 342: 1040– 1042.

5. Linhart A, Dostál O. Kardiologická onemocnění a diabetes mellitus In: Perušičová J, Češka R (eds). Kardiabetes: kardiovaskulární choroby a diabetes mellitus. Brno: Facta Medica 2009: 49– 64.

6. Laing SP, Swerdlow AJ, Slater SD et al. Mortality from heart disease in a cohort of 23,000 patients with insulin‑treated diabetes. Diabetologia 2003; 46: 760– 765.

7. DECODE Study Group, European Diabetes Epidemiology group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688– 696.

8. DECODE Study Group. Consequences of the new diagnostic criteria for diabetes in older men and women. Diabetes Care 1999; 22: 1667– 1671.

9. de Vegt F, Dekker JM, Ruhé HG et al. Hyperglycaemia is associated with all‑cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42: 926– 931.

10. Selvin E, Marinopoulos S, Berkenblit G et al. Meta‑analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421– 431.

11. Meigs JB, Nathan DM, D’Agostino RB Sr et al. Fasting and postchallenge glycaemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002; 25: 1845– 1850.

12. Woerle HJ, Pimenta WP, Meyer C et al. Diagnostic and therapeutic implications of relationships between fasting, 2- hour postchallenge plasma glucose and hemoglobin A1C values. Arch Intern Med 2004; 164: 1627– 1632.

13. Blake DR, Meigs JB, Muller DC et al. Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 2004; 53: 2095– 2100.

14. Tominaga M, Eguchi H, Manaka H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care 1999; 22: 920– 924.

15. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371: 1800– 1809.

16. Lago RM, Nesto RW. Type 2 diabetes and coronary heart disease: focus on myocardial infarction. Curr Diab Rep 2009;9: 73– 78.

17. Prázný M. Mikroangiopatie a diabetes mellitus. In: Perušičová J, Češka R (eds). KARDIABETES: kardiovaskulární choroby a diabetes mellitus. Brno: Facta Medica 2009: 38– 45.

18. Šimek S, Šimková R. Srdce a diabetes mellitus. In: Vojáček J, Kettner J (eds). Klinická kardiologie. Hradec Králové: Nucleus HK 2009: 817– 852.

19. Zarich SW, Nesto RW. Implications and treatment of acute hyperglycaemia in the setting of acute myocardial infarction. Circulation 2007; 115: e436– e439.

20. Mietinnen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care 1998; 21: 69– 75.

21. Daemen J, Garcia‑ Garcia HM, Kukreja N et al. The long ‑term value of sirolimus and paclitaxel‑eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28: 26– 32.

22. Roffi M, Chew DP, Mukherjee D et al. Platelet glycoprotein IIb/ IIIa inhibitors reduce mortality in diabetic patients with non‑ST segment elevation acute coronary syndromes. Circulation 2001; 104: 2767– 2771.

23. Detre K, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients. A comparison of the randomised and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99: 633– 640.

24. Kvapil M. Co přinesly výsledky studie BARI 2D. Medical Tribune 2009; 1.

25. Češka R et al. Cholesterol a ateroskleróza, léčba dyslipidémií. Praha: Triton 2005: 171– 202.

26. Widimský J jr, Cífková R, Špinar J et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze: verze 2007. Cor et Vasa 2008; 50: K5– K22.

27. Turnbull F, Neal B, Pfeffer M et al. Blood pressure‑dependent and independent effects of agents that inhibit the renin‑angiotensin system. J Hypertens 2007; 25: 951– 958.

28. Prázný M. Léčba hypertenze jako prevence diabetu In: Perušičová J, Češka R (eds). KARDIABETES: kardiovaskulární choroby a diabetes mellitus. Brno: Facta Medica 2009: 113– 121.

29. Scott R, Best J, Forder P et al. FIELD Study investigators. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristic short‑term effects of fenofibrate. Cardiovasc Diabetol 2005; 4: 13.

30. Graham I, Atar D, Borch‑ Johsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Hear J 2007; 28: 2375– 2414.

31. Laine L. Review article: gastrointestinal bleeding with low‑dose aspirin‑what’s the risk? Aliment Pharmacol Ther 2006; 24: 897– 908.

32. Cífková R, Býma S, Češka R et al. Za společnou pracovní skupinu. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Vnitř Lék 2005; 51: 1021– 1036.

33. Buse JB, Ginsberg HN, Baknis GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the America Heart Association and the American Diabetes Association. Circulation 2007; 115: 114– 126.

34. UK Prospective Diabetes Study (UKPDS)Group. Effect of intensive blood‑ glucose control with metformin on complications in overweight patients with type 2 diabetes. UK Prospective Study Group (UKPDS 34). Lancet 1998; 352: 854– 865.

35. Pelikánová T. Změnila nová perorální antidiabetika a výsledky intervenčních studií (DREAM, ADOPT) strategii léčby diabetu 2. typu? Remedia 2007; 17: 119– 125.

36. Chiasson JL, Josse RG, Gomis R et al. STOP‑ NIDDM Trial Research group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP‑ NIDDM trial. JAMA 2003; 290: 486– 494.

37. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular events): a randomised controlled trial. Lancet 2005; 366: 1279– 1289.

38. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643– 2653.

39. Holman RR, Paul SK, Bethel MA et al. 10‑year follow‑up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577– 1589.

40. Perušičová J. Prevence a léčba kardiabetu. In: Perušičová J, Češka R (eds). Kardiabetes: kardiovaskulární choroby a diabetes mellitus. Brno: Facta medica 2009: 203– 206.

41. Radermecker RP, Philips JC, Jandrain B et al. Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA‑ Diabetes trials. Rev Med Liege 2008; 63: 511– 518.

42. Kvapil M, Honka M. O studii ADVANCE znovu v Montrealu. Medical Tribune 2009; 31.